Natural history and outcomes in localised immunoglobulin light-chain amyloidosis: A long-term observational study

The Lancet Haematology

Volumn 2, Issue 6, 2015, Pages e241-e250

  Mahmood, Shameem ^a   Bridoux, Frank ^b   Venner, Christopher P ^c   Sachchithanantham, Sajitha ^a   Gilbertson, Janet A ^a   Rowczenio, Dorota ^a   Wagner, Thomas ^a   Sayed, Rabya ^a   Patel, Ketna ^a   Fontana, Marianna ^a   Whelan, Carol J ^a   Lachmann, Helen J ^a   Hawkins, Philip N ^a   Gillmore, Julian D ^a   Wechalekar, Ashutosh D ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b Department of Nephrology ^*  (France)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; APOLIPOPROTEIN A1; IMMUNOGLOBULIN LIGHT CHAIN;

ADULT; AMYLOIDOSIS; ARTICLE; BIOPSY; BLADDER; CLINICAL FEATURE; FEMALE; GASTROINTESTINAL TRACT; GENE SEQUENCE; HUMAN; LARYNX; LUNG NODULE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MUTATION; OBSERVATIONAL STUDY; PRIORITY JOURNAL; SKIN NODULE; TONSIL; AGED; LONGITUDINAL STUDY; PROGNOSIS; SURVIVAL RATE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AMYLOIDOSIS; BIOPSY; FEMALE; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL RATE;

EID: 84955204936     PISSN: None     EISSN: 23523026     Source Type: Journal    
DOI: 10.1016/S2352-3026(15)00068-X     Document Type: Article

References (28)

1. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003; 349: 583-96.
2. Sipe JD, Benson MD, Buxbaum JN, et al. Nomenclature 2014: amyloid fibril proteins and clinical classification of the amyloidosis. Amyloid 2014; 21: 221-24.
3. Westermark P. Localized AL amyloidosis: a suicidal neoplasm? Ups J Med Sci 2012; 117: 244-50.
4. Westermark P, Benson MD, Buxbaum JN, et al. A primer of amyloid nomenclature. Amyloid 2007; 14: 179-83.
5. Hawkins PN, Lavender JP, Pepys MB. Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component. New Engl J Med 1990; 323: 508-13.
6. Office of National Statistics. Historic and projected mortality data from the period and cohort life tables, 2012-based, UK, 1981-2062. 2013. http://www.ons.gov.uk/ons/dcp171778_345078.pdf (accessed Feb 25, 2015).
7. Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis. Am J Hematol 2005; 79: 319-28.
8. Charlot M, Seldin DC, O'Hara C, Skinner, Sanchorawala V. Localized amyloidosis of the breast: a case series. Amyloid 2011; 18: 72-75.
9. Cowan AJ, Skinner M, Seldin D, et al. Amyloidosis of the gastrointestinal tract: a 13-year, single-center, referral experience. Haematologica 2013; 98: 141-46.
10. Osnoss KL, Harrell DD. Isolated mediastinal mass in primary amyloidosis. Chest 1980; 78: 786-88.
11. Grogg KL, Aubry MC, Vrana JA. Nodular pulmonary amyloidosis is characterized by localized immunoglobulin deposition and is frequently associated with an indolent B-cell lymphoproliferative disorder. Am J Surg Pathol 2013; 37: 406-12.
12. Lachmann HJ, Gallimore R, Gillmore JD, et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol 2003; 122: 78-84.
13. Kumar S, Dispenzieri A, Katzmann JA, et al. Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features. Blood 2010; 116: 5126-29.
14. Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Melton LJ 3rd. Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance: the original Mayo Clinic series 25 years later. Mayo Clin Proc 2004; 79: 859-66.
15. Fernand JP, Bridoux F, Kyle RA, et al. How do I treat monoclonal gammopathy of renal significance (MGRS). Blood 2013;122: 3583-90.
16. Fu J, Seldin D, Berk J, et al. Lymphandeopathy as a manifestation of amyloidosis: a case series. Amyloid 2014; 21: 256-60.
17. Weiss BM, Hebreo J, Cordaro DV, et al. Increased serum free light chains precede the presentation of immunoglobulin light chain amyloidosis. J Clin Oncol 2014; 32: 2699-704.
18. Setoguchi M, Hoshii Y, Kawano Hea. Analysis of plasma cell clonality in localized AL amyloidosis. Amyloid 2000; 7: 41-45.
19. Miyamoto T, Kobayashi T, Makiyama M, et al. Monoclonality of infiltrating plasma cells in primary pulmonary nodular amyloidosis: detection with polymerase chain reaction. J Clin Pathol 1999; 52: 464-67.
20. Krishnan J, Chu W, Elrod JP, Frizzera G. Tumoral presentation of amyloidosis (amyloidomas) in soft tissues. A report of 14 cases. Am J Clin Pathol 1993; 100: 135-44.
21. Lim JK, Lacy MQ, Kurtin PJ, Kyle RA, Gertz MA. Pulmonary marginal zone lymphoma of MALT type as a cause of localised pulmonary amyloidosis. J Clin Pathol 2001; 54: 642-46.
22. Kambouchner M, Godmer P, Guillevin L, Raphael M, Droz D, Martin A. Low grade marginal zone B cell lymphoma of the breast associated with localised amyloidosis and corpora amylacea in a woman with long standing primary Sjogren's syndrome. J Clin Pathol 2003; 56: 74-77.
23. Meijer JM, Schonland SO, Palladini G, et al. Sjögren's syndrome and localized nodular cutaneous amyloidosis: coincidence or a distinct clinical entity? Arthritis Rheum 2008; 58: 1992-99.
24. Mekinian A, Jaccard A, Soussan M, et al. 18F-FDG PET/CT in patients with amyloid light-chain amyloidosis: case-series and literature review. Amyloid 2012; 19: 94-98.
25. Yoshida A, Borkar S, Singh Bea, Ghossein RA, Schoder H. Incidental detection of concurrent extramedullary plasmacytoma and amyloidoma of the nasopharynx on [18F]fluorodeoxyglucose positron emission tomography/computed tomography. J Clin Oncol 2008; 26: 5817-19.
26. Truong MT, Kachnic LA, Grillone GA, et al. Long-term results of conformal radiotherapy for progressive airway amyloidosis. Int J Radiat Oncol Biol Phys 2012; 83: 734-39.
27. Neben-Wittich M, Foote R, Kalra S. External beam radiation therapy for tracheobronchial amyloidosis. Chest 2007; 132: 262-67.
28. Wechalekar A, Schonland SO, Kastritis E, et al. European Collaborative Study of treatment outcomes in 346 patients with systemic AL amyloidosis with Mayo stage III disease. Blood 2013; 30: 989-95.